<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001358285</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001401667</issuerCik>
      <issuerName>PUMA BIOTECHNOLOGY, INC.</issuerName>
      <secFileNumber>001-35703</secFileNumber>
      <issuerAddress>
        <com:street1>10880 WILSHIRE BLVD.</com:street1>
        <com:street2>SUITE 2150</com:street2>
        <com:city>LOS ANGELES</com:city>
        <com:stateOrCountry>CA</com:stateOrCountry>
        <com:zipCode>90024</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>(424) 248-6500</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>AUERBACH ALAN H</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Officer</relationshipToIssuer>
        <relationshipToIssuer>Director</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Muriel Siebert &amp; Co., Inc.</name>
        <address>
          <com:street1>4141 NE 2nd Avenue, Suite 201</com:street1>
          <com:city>Miami</com:city>
          <com:stateOrCountry>FL</com:stateOrCountry>
          <com:zipCode>33137</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>41396</noOfUnitsSold>
      <aggregateMarketValue>187316.90</aggregateMarketValue>
      <noOfUnitsOutstanding>47571332</noOfUnitsOutstanding>
      <approxSaleDate>01/03/2024</approxSaleDate>
      <securitiesExchangeName>NASDAQGS</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>02/17/2021</acquiredDate>
      <natureOfAcquisitionTransaction>Restricted Stock Unit Grant</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>PUMA BIOTECHNOLOGY, INC</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>149951</amountOfSecuritiesAcquired>
      <paymentDate>02/17/2021</paymentDate>
      <natureOfPayment>Compensation for Services Rendered</natureOfPayment>
    </securitiesToBeSold>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>03/03/2022</acquiredDate>
      <natureOfAcquisitionTransaction>Restricted Stock Unit Grant</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>PUMA BIOTECHNOLOGY, INC.</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>168824</amountOfSecuritiesAcquired>
      <paymentDate>03/03/2022</paymentDate>
      <natureOfPayment>Compensation for Services Rendered</natureOfPayment>
    </securitiesToBeSold>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>02/10/2023</acquiredDate>
      <natureOfAcquisitionTransaction>Restricted Stock Unit Grant</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>PUMA BIOTECHNOLOGY, INC.</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>186403</amountOfSecuritiesAcquired>
      <paymentDate>02/10/2023</paymentDate>
      <natureOfPayment>Compensation for Services Rendered</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <noticeSignature>
      <noticeDate>01/03/2024</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>12/17/2020</planAdoptionDate>
      </planAdoptionDates>
      <signature>/s/ Chris Culotta, Attorney-in-Fact for Alan H. Auerbach</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
